BioMarin shares defended, trial suspension not new, says Barclays - Barclays said the suspension of BioMarin's gene suspension study in severe hemophilia A patients is a reflection that the company had previously stopped dosing after reports of elevated liver enzymes. This update is a lag between the announcement and trial entry update and was previously discussed on the Q1 call and at the R&D day. The firm said BioMarin is currently working on a revised protocol that will likely include the use of of prophylactic steroids prior to administration of the therapy. Barclays's reiterates its Overweight rating and $105 price target on shares.